Market Overview

Why Axovant's Stock Is Trading Lower Today

Why Axovant's Stock Is Trading Lower Today

Axovant Gene Therapies (NASDAQ: AXGT) shares were trading lower on Tuesday after the company reported its six-month follow-up data from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD gene therapy.

Axovant Gene Therapies is a clinical-stage company that is focused on gene therapy for neurodegenerative diseases. The company is developing its pipeline for the treatment of debilitating diseases, including Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis. It currently has three clinical-stage programs which include AXO-Lenti-PD program for Parkinson's disease, AXO-AAV-GM1 program for GM1 gangliosidosis, and AXO-AAV-GM1 program for GM2 gangliosidosis (including Tay-Sachs and Sandhoff diseases).

Axovant Gene Therapies shares traded down 22.82% to $4.34 on Tuesday. The stock has a 52-week high of $6.93 and a 52-week low of $1.41.


Related Articles (AXGT)

View Comments and Join the Discussion!

Posted-In: Wy it's movingNews Penny Stocks Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at